ENDRA Life Sciences Inc. (NDRA): Nasdaq/NYSE listing notice — ENDRA receives Nasdaq delisting notice for equity falling below $2.5M minimum

ENDRA Life Sciences Inc.

Nasdaq notified ENDRA on Apr 20, 2026 that stockholders' equity of $2,260,120 as of Dec 31, 2025 fails the $2.5M minimum.
Company intends to timely request a hearing before Nasdaq Hearings Panel to stay delisting.
ENDRA previously regained compliance in Nov 2025 but is now non-compliant again after annual report filing.
No assurance that the company will regain compliance or succeed in appeal; delisting remains possible.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ENDRA Life Sciences Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 20, 2026, the Staff issued a letter to the Company indicating that, because the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025 was $2,260,120, the Company is no longer in compliance with Minimum Stockholders’ Equity Requirement. The Staff’s letter indicated that the Company’s non-compliance would result in the delisting of the Company’s securities from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to timely request a hearing before the Panel, which

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-045885

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.